Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Surgical Science Sweden ABSUSRF -2.20%82 EV-to-EBITDA is 12.45 as of Jul. 23, 2026, which is 72% below its 10-year median of 44.46. GuruFocus rates SUSRF with a GF Score™ of 82/100 and a GF Value™ of $14.25 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 506 Healthcare Providers & Services companies, Surgical Science Sweden AB ranks worse than 57.11% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Surgical Science Sweden AB's enterprise value is $91.4 Mil.
Surgical Science Sweden AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $7.3 Mil. Therefore, Surgical Science Sweden AB's EV-to-EBITDA for today is 12.45.
The historical rank and industry rank for Surgical Science Sweden AB's EV-to-EBITDA or its related term are showing as below:
SUSRF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -993.85 Med: 44.46 Max: 561.93
Current: 12.93
During the past 11 years, the highest EV-to-EBITDA of Surgical Science Sweden AB was 561.93. The lowest was -993.85. And the median was 44.46.
SUSRF's EV-to-EBITDA is ranked worse than 57.11% of 506
companies
in the Healthcare Providers & Services industry
Industry Median: 11.075
vs SUSRF: 12.93
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Surgical Science Sweden AB (OTCPK:SUSRF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Surgical Science Sweden AB's PE Ratio (TTM) for today is calculated as:
Surgical Science Sweden AB's share price for today is $4.00.
Surgical Science Sweden AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.112.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Surgical Science Sweden AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Surgical Science Sweden AB EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Surgical Science Sweden AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Surgical Science Sweden AB's EV-to-EBITDA falls into.
Surgical Science Sweden AB's current Enterprise Value is $91.4 Mil.
Surgical Science Sweden AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Surgical Science Sweden AB (SUSRF) has a EV-to-EBITDA of 12.45 as of Jul. 23, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Surgical Science Sweden AB. This is 72% below median its historical median of 44.46. According to the industry distribution chart, Surgical Science Sweden AB ranks #289 out of 506 companies in the Healthcare Providers & Services industry, placing it in the top 57.1%.
Is Surgical Science Sweden AB's EV-to-EBITDA too high?
Surgical Science Sweden AB's current EV-to-EBITDA of 12.45 is 72% below median its 10-year median of 44.46. The Healthcare Providers & Services industry median EV-to-EBITDA is 11.08. Surgical Science Sweden AB's value of 12.45 is 12.4% above this industry median. Based on the distribution chart, Surgical Science Sweden AB ranks #289 out of 506 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Surgical Science Sweden AB has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Surgical Science Sweden AB's EV-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Surgical Science Sweden AB ranks #289 out of 506 companies for EV-to-EBITDA. This places Surgical Science Sweden AB in the lower half of its industry. The industry median EV-to-EBITDA is 11.08. Surgical Science Sweden AB's value of 12.45 is 12.4% above this benchmark. While the company's 10-year median is 44.46 vs. the industry median of 11.08, Surgical Science Sweden AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 11.08, based on 506 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Surgical Science Sweden AB's current EV-to-EBITDA of 12.45 is 12.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Surgical Science Sweden AB. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 11.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Surgical Science Sweden AB's current EV-to-EBITDA is 12.45, which is 72% below median its own 10-year median of 44.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surgical Science Sweden AB stock overvalued right now?
Based on GuruFocus' analysis, Surgical Science Sweden AB (SUSRF) is currently considered Significantly Undervalued. The stock's GF Value™ is $14.25, compared to a current price of $4.00 — trading 71.9% below its estimated fair value. The current EV-to-EBITDA is 12.45, which is 72% below median its 10-year median of 44.46 and 12.4% above the Healthcare Providers & Services industry median of 11.08. Surgical Science Sweden AB's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Surgical Science Sweden AB (SUSRF), the current EV-to-EBITDA is 12.45 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Surgical Science Sweden AB (SUSRF) Overvalued in 2026?
Based on GuruFocus' analysis, Surgical Science Sweden AB stock appears to be undervalued.
The current stock price of $4.00 is trading 71.9% below its estimated GF Value™ of $14.25.
GuruFocus considers Surgical Science Sweden AB to be Significantly Undervalued.
Key valuation signals for SUSRF:
EV-to-EBITDA: 12.45 (72% below median its 10-year median of 44.46)
GF Value™: $14.25 vs. price of $4.00 (71.9% below fair value)
Industry Position: 12.4% above the Healthcare Providers & Services median (#289 of 506)
No single metric tells the full story. See the SUSRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Surgical Science Sweden AB is a supplier of virtual reality simulators for medical training. The company's core is its proprietary software and hardware for simulating interactions between instruments and anatomy. It has two operating segments: Educational products include Proprietary brand medical simulator hardware and software for generic training of psycho-motor skills, instrument handling, and training for a large number of procedures and examinations prior to entering the clinical environment, as well as support and services. Industry/OEM includes simulation software for product-specific training of surgeons in robot-assisted surgery and other digitalized medical instruments, and also simulators for medical device companies.
82GF Score
Get the complete analysis for SUSRF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SUSRF has been successfully added to your 
